A Phase III Randomized Trial Comparing Adjuvant MK-3475 (Pembrolizumab) to Standard of Care Observation in Completely Resected Merkel Cell Carcinoma

What is the purpose of this trial?

This phase III trial studies how well pembrolizumab works compared to standard of care observation in treating patients with stage I-III Merkel cell cancer that has been completely removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.



Alliance Cooperative Group

Start Date: 06/11/2019

End Date: 10/31/2023

Last Updated: 06/12/2019

Study HIC#: 2000025163

Get Involved

For more information about this study, contact:
Neta Shanwetter Levit
+1 203-737-6247
neta.shanwetterlevit@yale.edu

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 1-877-978-8348.

Trial Image

Investigators

Harriet Kluger

Principal Investigator

Sub-Investigators